A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"
- Conditions
- Rosacea
- Interventions
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 1105
- Registration Number
- NCT03954444
- Locations
- 🇺🇸
Site 1, Lynchburg, Virginia, United States
Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg
- Conditions
- Asthma
- Interventions
- Drug: Placebo pressurized metered dose inhaler
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 1902
- Registration Number
- NCT03879837
- Locations
- 🇺🇸
Site 1, Spartanburg, South Carolina, United States
Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma
- Conditions
- Asthma
- Interventions
- Drug: Placebo Inhalation Powder
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 999
- Registration Number
- NCT03756883
- Locations
- 🇺🇸
Study Site 101, Miami Lakes, Florida, United States
Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension
- Conditions
- Cataract
- Interventions
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 448
- Registration Number
- NCT03499873
- Locations
- 🇺🇸
Key-Whitman Eye Center, Dallas, Texas, United States
Clinical Endpoint Study of Ivermectin 0.5% Lotion
- Conditions
- Head Lice
- Interventions
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 905
- Registration Number
- NCT03301649
- Locations
- 🇺🇸
Site 1, Miami, Florida, United States
Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis
- Conditions
- Atrophic Vaginitis
- Interventions
- Drug: Generic Estradiol Vaginal Cream USP, 0.01%Drug: Vehicle Vaginal Cream
- First Posted Date
- 2017-09-27
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 663
- Registration Number
- NCT03294538
- Locations
- 🇺🇸
Site Number 44, Tucson, Arizona, United States
🇺🇸Site Number 17, Tucson, Arizona, United States
🇺🇸Site Number 31, La Mesa, California, United States
A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea
- Conditions
- Rosacea
- Interventions
- Drug: Generic Azelaic Acid FoamDrug: Vehicle FoamOther: CleanserOther: SunscreenOther: TowelOther: Moisturizing Lotion
- First Posted Date
- 2017-09-19
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 924
- Registration Number
- NCT03287791
- Locations
- 🇺🇸
Investigative Site 2, Encino, California, United States
🇺🇸Investigative Site 10, La Mesa, California, United States
🇺🇸Investigative Site 19, Brandon, Florida, United States
An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis
- Conditions
- ACTINIC KERATOSIS
- Interventions
- Drug: Generic Ingenol MebutateDrug: Vehicle FoamDrug: Ingenol Mebutate (Picato®)
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 507
- Registration Number
- NCT03200912
- Locations
- 🇺🇸
Dermatology Specialists, Inc., Oceanside, California, United States
🇺🇸Horizons Clinical Research Ctr., LLC, Denver, Colorado, United States
🇺🇸The Center for Clinical and Cosmetic Research, Aventura, Florida, United States
Clinical Endpoint Study of Ivermectin 1% Cream
- Conditions
- Moderate to Severe Papulopustular Rosacea
- Interventions
- Drug: Placebo/Vehicle cream
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 630
- Registration Number
- NCT02840461
- Locations
- 🇺🇸
Investigator site 1, Arlington Heights, Illinois, United States
Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2020-05-29
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 587
- Registration Number
- NCT02791308
- Locations
- 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸Clinical Research Center of Alabama, Birmingham, Alabama, United States
🇺🇸Agave Clinical Research, LLC, Mesa, Arizona, United States